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ABSTRACT: Annotation and identiﬁcation of metabolite
biomarkers is critical for their biological interpretation in
metabolic phenotyping studies, presenting a signiﬁcant
bottleneck in the successful implementation of untargeted
metabolomics. Here, a systematic multistep protocol was
developed for the puriﬁcation and de novo structural
elucidation of urinary metabolites. The protocol is most
suited for instances where structure elucidation and
metabolite annotation are critical for the downstream
biological interpretation of metabolic phenotyping studies.
First, a bulk urine pool was desalted using ion-exchange resins
enabling large-scale fractionation using precise iterations of
analytical scale chromatography. Primary urine fractions were collected and assembled into a “fraction bank” suitable for long-
term laboratory storage. Secondary and tertiary fractionations exploited diﬀerences in selectivity across a range of reversed-
phase chemistries, achieving the puriﬁcation of metabolites of interest yielding an amount of material suitable for chemical
characterization. To exemplify the application of the systematic workﬂow in a diverse set of cases, four metabolites with a range
of physicochemical properties were selected and puriﬁed from urine and subjected to chemical formula and structure
elucidation by respective magnetic resonance mass spectrometry (MRMS) and NMR analyses. Their structures were fully
assigned as tetrahydropentoxyline, indole-3-acetic-acid-O-glucuronide, p-cresol glucuronide, and pregnanediol-3-glucuronide.
Unused eﬄuent was collected, dried, and returned to the fraction bank, demonstrating the viability of the system for repeat use
in metabolite annotation with a high degree of eﬃciency.
Metabolic proﬁling of human bioﬂuids by liquidchromatography−mass spectrometry (LC-MS) is
widely used in clinical and epidemiological studies. Improve-
ments in analytical technologies and automation of data
processing have made it possible to increase both the number
and throughput of sample analysis. In addition, technological
advancements allowing greater analytical sensitivity, precision,
and selectivity have led to the increase of the number of the
detectable chemicals providing greater metabolome coverage.
The extensive breadth of metabolic proﬁling data ensures that
metabolite annotation and identiﬁcation remain major bottle-
necks in the metabolic phenotyping workﬂow, with low
abundance metabolites, gut microbial cometabolites, secondary
metabolites (glucuronides and sulfates), and chemically
modiﬁed drug and diet related metabolites representing
speciﬁc challenges. Growth of publicly available databases
containing mass spectral reference data for thousands of
chemical species1−3 is limited by the availability of authentic
chemical standards, and the value of establishing method-
speciﬁc in-house databases (e.g., complete with chromato-
graphic retention time measurement) is further hampered by
the lack of consistency in standard chromatographic proﬁling
methods employed. Some in silico spectra prediction computa-
tional tools and pipelines4,5 are being developed,5−8 as well as
retention time prediction,9,10 chemical similarity,11 and
biological assumptions to extend the reach of generic
metabolite annotation capabilities beyond the limitations of
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reference data. However, to meet the emphasis placed on the
biological interpretation of speciﬁc biomarkers arising from
proﬁling studies, further advancements in de novo structure
elucidation are required to accelerate the identiﬁcation of
unknown metabolic markers of interest, ultimately mapping
the large chemical space of the human metabolome observable
by analytical proﬁling methods.
The two widely used analytical platforms that provide
information on molecular structure and elemental composition
of unknown chemicals are nuclear magnetic resonance (NMR)
spectroscopy12 and mass spectrometry (high-resolution MS
and tandem MS/MS).13 The combination of both techniques
can provide detailed chemical formula and structural
information leading to comprehensive annotation. This
approach is being widely employed in natural products
chemistry,14,15 as well as in drug discovery,16 and in drug
metabolism and metabolite discovery in the pharmaceutical
industry.17 Recently, multitechnique approaches have been
applied to both plant18,19 and bacterial20 metabolomics, while
LC-MS has been used to assist with the structural elucidation
of metabolites from NMR-based experiments.21
Traditionally in natural products chemistry, to generate the
required concentration of metabolites pure enough to annotate
via NMR spectroscopy preparative-scale liquid chromatog-
raphy or ﬂash chromatography systems are employed.22
However, these are often costly and are not available to
analytical laboratories who routinely perform metabolic
proﬁling studies using UHPLC-MS systems. The subsequent
application of NMR spectroscopy to structurally elucidate
features from LC-MS based metabolite proﬁling has its own
challenges. NMR spectroscopic analyses do not have the
sensitivity of LC-MS assays; therefore, large quantities (often
in the order of milligrams) of relatively pure material isolated
from bioﬂuids, such as blood (serum and plasma) or urine, are
required for structural elucidation.
Of the bioﬂuids commonly studied in human phenotyping
experiments, urine holds an advantage over blood products
because of the noninvasive collection of large volumes (e.g., via
routine 24 h collections which typically produce liters of
bioﬂuid per day and per person), making it an ideal starting
material for puriﬁcation and concentration for NMR structural
elucidation. In addition, urine is a key biological matrix within
metabolic proﬁling because it contains an extreme diversity of
chemical classes, including gut microbial cometabolites and
xenobiotics.23 Moreover, many metabolites present in blood
are excreted and can be detected in urine23, and many
metabolites circulating in blood may, therefore, be found in
urine and recovered in larger amounts for further spectroscopic
characterization.
At the same time, the urine matrix also poses chromato-
graphic challenges because of its high inorganic salt content. In
reversed-phase (RP) LC-MS analysis and fractionation, the
presence of large salt amounts can cause various problems with
both LC system and retention of the compounds, as well as
with their MS detection. The salts from the urine samples can
precipitate in the chromatographic column, and the amount of
precipitate can increase with subsequent injections under the
gradient conditions leading to a faster column degradation.
Salts present in the sample or mobile phase can have also a
strong inﬂuence on the solid−liquid equilibria that establish
during the chromatographic run, especially in the case of
ionized polar compounds.24 A high salt concentration can also
Figure 1. Workﬂow of the pipeline.
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impact the performance of NMR probes, decreasing the
sensitivity and making it diﬃcult to optimize experimental
parameters.
To leverage the availability of human urine, its potential for
use as a proxy matrix for systemic human and gut microbial
metabolism, and the general availability of analytical scale
instrumentation in metabolic phenotyping laboratories, we
designed and implemented a novel urine-based pipeline
solution that facilitates metabolite extraction, concentration,
and puriﬁcation using analytical scale systems coupled to a
fractionation system. Prior to the primary fractionation, a urine
pool underwent a desalting procedure using ion-exchange
resin, which allowed for high-precision RPLC separation on an
analytical scale system that demonstrated no degradation in
column performance.
The resulting workﬂow enables puriﬁcation and concen-
tration of small molecule metabolites from urine that is easily
implementable in analytical laboratories without the need for
specialist puriﬁcation LC systems. These puriﬁed metabolites
can be subsequently decoupled from the pipeline and studied
by a range of highly structural informative analytical
techniques, such as such as Magnetic Resonance Mass
Spectrometry (MRMS) or NMR. The eﬃcacy and systematic
deployment of the developed pipeline is demonstrated using a
set of unknown metabolites of various biochemical classes and
diﬀerent physicochemical properties.
■ MATERIALS AND METHODS
In-House MRC-NIHR National Phenome Centre
Reversed-Phase Metabolite Proﬁling Method. Pooled
bulk urine and all subsequent downstream fractions underwent
RP proﬁling using the method developed in-house at the
NIHR-MRC National Phenome Centre (NPC) at Imperial
College London described in detail in ref 25.
To brieﬂy summarize, RP urine proﬁling was completed
using a Waters Acquity UPLC system coupled to a Waters
Xevo G2 QToF mass spectrometer (Waters Corp., Milford,
MA, USA). LC separation was conducted on a 2.1 × 150 mm
HSS T3 column (Waters Corp., Milford, MA, USA)
maintained at 45 °C. Mobile phase ﬂow rate was of 0.6 mL/
min. A gradient was applied consisting of 0.1% formic acid in
water (A) and 0.1% formic acid in acetonitrile (B). Initial
conditions of 99% A were held at isocratic conditions for 0.1
min, followed by a linear gradient elution, 99% A to 45% A, in
9.9 min, and a ﬁnal rapid gradient phase, 45% A to 0% A in 0.7
min, prior to returning to initial conditions. Injection volume
was 2 μL.
Mass spectrometry optimization is described in detail in ref
25. To brieﬂy summarize, capillary voltage was set at 1.5 and
1.0 kV for positive and negative ionization, respectively. Cone
voltage (20 V), source oﬀset (80 V), StepWave 2 oﬀset (10 V),
and gas ﬂows of 150 L/h for cone gas and 1000L/h for
desolvation gas were consistent for both polarities.
Masslynx software (Waters, Manchester, U.K.) was used for
data acquisition and visual inspection.
Pipeline for Systematic Biomarker Isolation and De
Novo Structure Elucidation. An overview of the pipeline is
presented in Figure 1. First, urine from 6 volunteers was
collected and pooled. The urine was split into two identical
subpools. The ﬁrst underwent desalting using an ion exchange
protocol. The second was kept as a control. Both underwent
10-fold concentration by drying under a stream of nitrogen
(Biotage Turbovap Classic), followed by primary RPLC
fractionation creating both a desalted and a control fraction
bank of 120 fractions. All stages underwent proﬁling using LC-
MS so that the protocols could be compared. The desalted
fraction bank, which had greater chromatographic reproduci-
bility and long-term resolution, was utilized for downstream
secondary and tertiary fractionation. The ﬁnal fractions were
then decoupled from the pipeline and sent to NMR
spectroscopy and magnetic resonance mass spectrometry
(MRMS)traditionally known as Fourier transform ion
cyclotron resonance mass spectrometry (FTICR MS), or
simply Fourier transform mass spectrometry (FTMS) for
annotation. In some cases, tertiary fractionation can be
replaced with a computational puriﬁcation by using statistical
heterospectroscopy (SHY)27 in combination with NMR
spectroscopy proﬁling.
■ PIPELINE PHASE 1BULK URINE PREPARATION
Urine Collection. Individual urine was collected from a
volunteer group of mixed genders (n = 6) and at multiple
collection time points. No screening criteria were used to
assess the health status of the donors. A total of 2 L was
collected and pooled as described in ref 25. This was split into
two one-liter identical aliquots. Pool one was used as an
untreated control to assess the eﬀect of the desalting protocol.
Urine Desalting. Urine pool 2 underwent a desalting
process developed in-house using a two-step ion-exchange
protocol. Step one used Amberlite IR120 cation exchanger
(hydrogen form) (12 g per 500 mL of urine); pH readings
were taken and conﬁrmed acidic conditions resulting from the
release of hydrogen ions from the ion-exchange resin. Step two
consisted of the addition of 6 g of Amberlite IRN78 anion
exchanger (hydroxide form) per 500 mL of urine from step 1,
followed by pH reading and titration with additional Amberlite
IRN78 until neutral pH 7 was reached (resulting from the
release of hydroxide ions from the ion-exchange resin). The
urine supernatant was removed at this point.
Urine Concentration. One liter of both control and
desalted urine pools were then taken to dryness under a stream
of nitrogen and subsequently resuspended in 100 mL of
ultrahigh purity water (in-house Barnstead Diamond water
puriﬁcation system, Thermo Scientiﬁc, Waltham, MA, USA) to
give a ﬁnal 10-fold concentrated sample (10×). Both the
control and desalted urine pools underwent metabolite
proﬁling using the RPLC-MS method described above for
comparison.
■ PIPELINE PHASE 2GENERATION OF THE
FRACTION BANK
Primary Fractionation and Formation of the Fraction
Bank. A bank of 120 fractions was created for each of the two
concentrated urine pools using an identical analytical scale
system consisting of a Waters Acquity UPLC system. RPLC-
separation was achieved using a 4.6 mm × 150 mm Atlantis T3
column (Waters Corp., Milford, MA, USA). Postcolumn
solvent eﬄuent was split using a 1:20 post column splitter, with
1 part diverted to a Waters Xevo TQ-S mass spectrometer for
real-time monitoring and 20 parts diverted to a Waters
Fraction Collector III collection system.
Primary fractionation employed a linear gradient consisting
of 0.1% formic acid in water (A) and 0.1% formic acid in
methanol (B), which provided better resolution of late eluting
metabolites compared to acetonitrile when using large
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injection volumes (1 mL). Mobile phase ﬂow rate was 1 mL/
min. Initial conditions of 99% A were held at isocratic
conditions for 2.0 min, followed by a linear gradient elution of
99% A to 80% A in 13.0 min, which was followed by a linear
gradient of 80% A to 50% A in 7.0 min, and then 50% A to 0%
A in a further 4 min and isocratically held for a further 2 min at
0% A, prior to returning to initial conditions. To monitor the
interinjection precision of the fractionation, full scan data were
collected on a Waters Xevo TQ-S mass spectrometer, using
single mass unit resolution. Data were collected in both
positive ionization mode (100−1200 Da), and negative
ionization mode (100−1200 Da). Masslynx software (Waters,
Manchester, U.K.) was used for data acquisition and visual
inspection.
One hundred replicates of 1 mL injection volume underwent
LC separation. Individual fractions were collected for 15 s
across the run creating a bank of 120 fractions. The LC-MS
system was fully cleaned, and a new column was used for the
fractionation of both control and desalted urine. The
remaining fractions were stored at −80 °C in 50 mL Falcon
tubes until use.
Fraction Bank Metabolite Mapping and Assessment
of the Desalting Protocol. Subaliquots (100 μL) of each
collected fraction (from both control and desalted urine) were
transferred to 96-well plates and dried under a stream of
nitrogen. Dried plates were then resuspended in ultra-high-
purity water (in-house Barnstead Diamond water puriﬁcation
system, Thermo Scientiﬁc, Waltham, MA, USA) and analyzed
using the RP method described above. Raw data underwent
peak picking using Progenesis QI software (Nonlinear
Dynamics, Newcastle upon Tyne, UK). This resulted in a
“map” of metabolite locations within the fraction bank.
■ PIPELINE PHASE 3PROOF OF CONCEPT
METABOLITE ANNOTATION
Proof of Concept Feature Selection. To demonstrate
the applicability of the de novo annotation protocol, four target
compounds were selected for annotation as proof of concept.
The four features were selected from the reversed-phase
proﬁling method to reﬂect a range of retention times and
physicochemical properties of metabolites. Two of the features
were selected from the same fraction from the fraction bank to
demonstrate the requirement for secondary and tertiary
isocratic fractionations. The fraction bank location matrix
described above facilitates the selection of the fraction with the
maximum concentration of the feature of interest. The fraction
containing the highest concentration of the feature of interest
was selected for downstream isocratic puriﬁcation and is
described in Table 1.
Secondary and Tertiary Isocratic Fractionation.
Secondary and tertiary fractionation was completed using
isocratic separation. To streamline the method development
time, a reference set of conditions was created using a
combination of diﬀerent reversed-phase columns and eluents
presented in Table S1.
These reference conditions were initially used to identify a
developmental start point and modiﬁed accordingly to obtain
maximum chromatographic resolution. This hybrid approach
of using an in-house condition library combined with bespoke
modiﬁcation signiﬁcantly reduced the overall chromatographic
development time, while maintaining maximum isocratic
chromatographic resolution of fractions.
The ﬂow rate was 1 mL/min, and the column temperature
was 35 °C for all instances for all chromatographic conditions.
Full scan data (50−1200 Da) in both positive and negative
ionization modes were collected on a Waters Xevo G2 QTOF-
MS.
Following the secondary fractionation, the obtained
subfractions underwent metabolite proﬁling using the in-
house RP metabolite proﬁling analytical method.25 Sub-
fractions containing the feature of interest were pooled and
taken to dryness under a stream of nitrogen, before
resuspension in a mobile phase (2.2 mL) that matched the
isocratic conditions of tertiary fractionation. Puriﬁed features
of interest were pooled for downstream decoupled analysis
including NMR and MRMS, assisting de novo structural
elucidation.
MS/MS Analysis of Concentrated Puriﬁed Samples.
MS/MS fragmentation analysis was completed with a Waters
Acquity UPLC system coupled to a Waters Xevo G2 QToF
mass spectrometer (Waters Corp., Milford, MA, USA). The
chromatographic method used the same conditions as the in-
house RP proﬁling method25 with the same mass spectrometry
source conditions. MS/MS target selection was performed
using unit mass selection via the quadrupole with varying
collision energy (5, 10, 20, 30, and 40 V) or a collision energy
voltage ramp was employed in the collision cell to facilitate
fragmentation (10−45 V).
MRMS Analysis. Magnetic resonance mass spectra
(MRMS) were acquired with a Bruker solariX 2xR (Bruker
Daltonics, Billerica, MA, US) using electrospray ionization
(ESI) and direct infusion with syringe pump. Mass spectra
were acquired with a mass resolution of 1.350.000 at m/z 200
using quadrupolar detection. Sixty-four single scans were
added for the ﬁnal mass spectrum (the details are presented in
Supporting Information (SI)). Isotopic ﬁne structure calcu-
lation was performed with DataAnalysis software (Bruker
Daltonics, Billerica, MA, US).
NMR Analysis. The dried fractions of the puriﬁed
metabolites were resuspended in 150 μL of LC-MS grade
water or the mixture of D2O 99% D (Sigma-Aldrich)
containing 10% H2O to avoid the disappearance of any
NMR signals due to the exchange with the solvent; 144 μL of
this solution was transferred into an Eppendorf tube together
with 16 μL of D2O containing 1 mg/mL of trimethylsilylpro-
panoic acid (TSP) (Sigma-Aldrich). The solution was vortexed
for 1 min and then centrifuged at 12000g for 5 min at 4 °C;
Table 1. Table of Four Initially Unannotated Metabolite
Features Selected from RP LC-MS Urinary Metabolic
Phenotyping Methods That Are Employed by the MRC-
NIHR National Phenome Centre25a
feature
QTOF-MS
observed m/z
(ES+)
QTOF-MS
observed m/z
(ES−)
RT in RP
UHPLC-MS
(min)
fraction
bank
maximumb
A 367.150 365.134 2.01 44
B 374.085 350.087 4.38 87
C NA 283.082 4.29 87
D NA 495.297 9.24 117
aThe metabolite features were selected because of their range of
retention times in RP chromatography, suggesting diﬀerent hydro-
phobicity, and therefore challenging the protocol. NA = no ion
observed in respective polarity. bFraction bank maximum refers to the
fraction bank stored fraction (1−120) that contains the highest
concentration of the feature of interest.
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155 μL of this solution was transferred into a 3 mm NMR
tube. This protocol was adapted from the publication of Dona
et al.26 using D2O with TSP instead of the phosphate buﬀer
solution as there was no need to control pH of the puriﬁed
samples.
1H NMR spectra were acquired using either a 600 MHz
Bruker Avance III HD spectrometer equipped with a BBI room
temperature probe, z-gradients, and high-order shims or a 600
MHz Bruker Avance III spectrometer equipped with a Cryo-
TCI triple resonance CryoProbe. A pulse sequence with two
presaturation periods to deplete water signal was used to
obtain the 1D data. Standard Bruker IVDr methods were used
for fraction proﬁling by NMR26 of the puriﬁed metabolites or
their subfractions. 1H NMR general proﬁle was acquired with a
higher number of scans to increase the signal-to-noise ratio
when required due to low concentration. Other 1H NMR
parameters were kept as previously described.26 A range of 2D
NMR spectroscopy experiments including J-resolved, 1H,1H−
COSY, 1H,1H-TOCSY, 2D 1H,1H-NOESY, 1H,13C-HSQC,
and 1H,13C-HMBC were performed for structural elucidation
of the puriﬁed metabolites (the details are presented in SI).
Data Processing and Analysis. Peak picking of raw LC-
MS data was completed using Progenesis QI software
(Nonlinear Dynamics, Newcastle upon Tyne, UK). This
provided a matrix of features within each fraction and was
utilized as a feature reference location map to facilitate the
identiﬁcation of the fraction of maximum concentration for
each feature of interest.
The subfractions obtained from isocratic puriﬁcation of the
metabolite of interest were proﬁled by 1H NMR using the
protocol described by Dona et al. for human urine samples.26
Fourier transform, phasing, baseline correction, and calibration
were done after acquisition using TopSpin 3.5 (Bruker BioSpin
GmbH, Rheinstetten, Germany) and then transferred to
MATLAB R2016a (Mathworks) as a matrix of intensities for
each part per million value of the spectra. All peaks detected in
the UHPLC-MS proﬁles of the subfractions of the metabolites
of interest were integrated using TargetLynx software (Waters,
Manchester, U.K.) and transferred as a matrix of peak areas to
MATLAB R2016a (Mathworks). These two matrices were
combined to perform statistical spectroscopic analysis
(SHY).27 The MS vector of a peak area was correlated to
the full-scan NMR spectra using Spearman correlation to infer
the linkage of the MS signals and the NMR peaks of a
metabolite.
Principal component analysis (PCA) was performed in
SIMCA 14.1 (Umetrics, Sweden).
■ RESULTS AND DISCUSSION
Pipeline Phase 1Bulk Urine Preparation. The
pipeline uses an initial one-liter volume of urine to create
the fraction bank. The need for a large volume is a potential
limitation of the pipeline as samples from clinical studies are
often volume-limited. However, many clinically relevant
metabolites (e.g., disease diagnostics or prognostics) are also
typically present in the bioﬂuids of healthy individuals.
Therefore, the generation of the fraction bank can be
performed with urine collected from volunteer populations
or purchased from commercial suppliers. In this regard urine is
an ideal bioﬂuid for the pipeline due to the possibility for the
noninvasive collection of large volumes (e.g., via routine 24h
collections which typically produce liters of bioﬂuid per day
and per person). Where key biomarker metabolites are disease
or subpopulation speciﬁc, the pipeline can be applied to urine
obtained from those individuals or subgroups.
Assessment of Desalting Urine. Urine is characterized by
the high content of inorganic salts, and their increased amount
in a preconcentrated urine pool in reversed-phase (RP) LC-
MS analysis can cause various problems with both the LC
system and retention of the compounds as well as with their
MS and NMR detections. Prior to fractionation a urine pool
underwent a desalting procedure using ion-exchange resin
(Figure 1).
The eﬀect the desalting step caused on the urine proﬁle by
MS is displayed in Figure S1 as heat map plots of each fraction
(number 1−120) against metabolite features ordered by RP
retention time. Panel A shows the untreated control urine
where fractions 1−25 (green circled) appear as a wide band
suggesting poor chromatographic resolution and greater
breakthrough of metabolites through lack of retention. The
authors believe this to be as a result of increased salt content
having a detrimental eﬀect on the chromatographic column.
Metabolite features are also visibly distributed across more
fractions in control urine (represented by wider bands
spanning more fractions in the heat map). On the other
hand, the desalted urine heat map (Figure S1a) shows a more
linear distribution, while the control urine heat map has a
sigmoidal shape, demonstrating a more even distribution of
metabolites in the fractionation of the desalted urine.
When operating at analytical scale the number of repeat
injections has to be increased to obtain the concentrations
required, therefore precision of replication is critical. To
further assess the fractionation quality and stability we used
principal component analysis (PCA) that should reﬂect in the
scores plot similarities in unit mass resolution proﬁles acquired
for each 1 mL injection (Figure S2). The scores for all 100
proﬁles of desalted 10× urine are tightly clustered together in
comparison to the scores of 100 proﬁles of untreated 10×
urine broadly spread across the PC2. This highlights how
fractions coming from desalted concentrated urine present
more stable retention times for metabolites, increasing
replicate precision and allowing higher column loading,
resulting in a more eﬃcient puriﬁcation process. The presented
desalting approach is opposite to a traditional use of ion-
exchange columns for the extraction of charged molecules of
polar metabolites from biological samples with their sub-
sequent removal from the resin using acid or base solution and
analysis.25 Therefore, it is unquestionable that along with the
salts the protocol decreases the concentration of some of the
most polar charged metabolites altering the overall metabolic
proﬁle of the desalted urine when compared to the original
one. However, the overall beneﬁt to increasing chromato-
graphic precision was felt by the authors to outweigh the loss
of some metabolite material. To date, no feature of interest
that has been through the protocol for annotation has been lost
by the desalting protocol.
Pipeline Phase 2Generation of the Fraction Bank.
Primary RP (RP) fractionation of desalted urine resulted in the
collection of 120 fractions which formed a fraction bank
repository stored at −80 °C. Each fraction was proﬁled using
the in-house RP phenotyping method in both positive and
negative ionization modes. A feature map was created for each
fraction in the bank enabling identiﬁcation of those fractions
containing features of interest. When these were found to
reside in multiple fractions, the mapping enabled selection of
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the fraction with their greatest concentration for downstream
isocratic analysis.
To streamline the collection and initial mapping process, all
eluent was recollected for subsequent isocratic fractionations.
Downstream fractions that contained the feature of interest
were collected and progressed to further puriﬁcation and
analysis, while the remaining “waste” eluent was dried,
resuspended in water, and returned to the −80 °C fraction
bank (Figure S3).
While drying and transfer loss inevitably occurs, the general
metabolic proﬁle is kept across the chromatogram. This novel
fraction bank approach extends the lifetime of each urine pool
and streamlines the overall pipeline enabling faster annotation
without the need of a new urine collection for subsequent
feature assignments.
Selection of Biomarkers for the Proof-of-Concept. To
demonstrate the protocol and as proof of concept, four
metabolite features were selected for de novo annotation.
Selected features represented a variation of retention times
from the in-house RP metabolic phenotyping assay (Table 1).
MS/MS fragmentation data suggested some structural proper-
ties of the metabolites.
Feature A eluted at 2.01 min on the phenotyping assay and
was selected because it is a relatively polar species. MS/MS
fragmentation had suggested that the feature was not a phase II
metabolite (e.g., a glucuronide or sulfate), and therefore would
produce a diﬀerent challenge to the protocol than B, C, and D.
MS/MS fragmentation indicated that Feature B (retention
time of 4.38 min) and D (retention time of 9.24 min) were
both glucuronides; however, a retention time separation of
4.86 min, suggested diﬀerent structural families. Feature B was
selected as it eluted closely to two isomers and would therefore
be an appropriate challenge for the protocol.
Feature C eluted in the same fraction as B, and it was
selected to demonstrate the requirement of secondary and
tertiary fractionations in relation to Feature B, and the
beneﬁcial implementation of statistical heterospectroscopy in
the protocol.
Secondary and tertiary conditions were selected for each of
the metabolite features of interest based on the generation of
the in-house isocratic reference conditions (Table S1). Two
complementary sets of separation conditions were chosen that
best isolated each of the features of interest. This work ﬂow
was developed to streamline the pipeline and create a “walk-
up” design, which greatly reduces the time required for each
feature puriﬁcation as time-consuming customizable method
development is bypassed.
Structure Elucidation of Urinary BiomarkersFeature A.
Feature A (Table 1) was the most polar of the selected
metabolites eluting at 2.01 min in the RP chromatography
metabolic proﬁling method described. Its puriﬁcation using
analytical scale RP chromatography required the highest
percentage of the aqueous phase A, employing 90% in the
secondary fractionation and 99% in the tertiary fractionation
(Table S1).
Initial HRMS data collected by QTOF-MS generated the
molecular formula C17H22N2O7 (Waters i-FIT elemental
composition calculator). The search of candidate structures
in Pubchem28 returned 605 theoretical candidates while
HMDB yielded two theoretical metabolites tetrahydropentoxy-
line and semilepidinoside B. QTOF MS/MS analysis
performed on starting urine material (Figure S4) gave the
main fragment ion at m/z 245.094 indicating loss of 120 Da
characteristic of C-glycosides.29 Tetrahydropentoxyline is a C-
glycoside while semilepidinoside is an O-glycoside therefore
tetrahydropentoxyline became the most likely candidate.
Figure 2. Structures of the UHPLC-MS features A−D puriﬁed from urine using the proposed pipeline and characterized by MS, NMR, and MRMS
spectroscopic analyses.
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Additionally, tetrahydropentoxyline has been previously
reported as a metabolite excreted in urine of normal subjects.30
Feature A was found to be at a maximum concentration in
fraction bank 44. This was used for secondary and tertiary
puriﬁcation using the conditions in Table S1. Following this, a
ﬁnal puriﬁed collection of feature A was sent for downstream
NMR and MRMS analysis.
MRMS (Figure S5) conﬁrmed the elemental composition
C17H22N2O7, while complete structural elucidation of feature A
was then performed by NMR spectroscopy. The result of
which was consistent with previously reported data.30
The full assignment of the structure of teterahydropentoxy-
line puriﬁed in this work (Figure 2) is presented in the Table
S2 together with the 2D NMR data Figures S6 and S7.
Structure Elucidation of Urinary BiomarkersFeature B.
Feature B was observed in RP metabolite proﬁling in both
positive and negative polarities (ES+ and ES−) eluting at 4.37
min. In ES+, the sodium adduct ion was dominant and the
deprotonated ion was dominant in ES− 374.085 m/z and
350.088 m/z, respectively. The tube location in the fraction
bank that contained the highest amount of feature B was
identiﬁed as 87; this was used for secondary and tertiary
isocratic puriﬁcation.
Feature B was selected for a proof of concept as it presented
a number of signiﬁcant challenges, including chromatographic
elution with nearby peaks of an identical m/z, and chromato-
graphic coelution with a peak of high intensity and
concentration.
Feature B Challenge 1: Chromatographic Coelution. The
ﬁrst challenge that Feature B presented to the pipeline was that
it existed in a complicated space in the chromatographic run
(Figure S8). Feature B directly coeluted with a feature of high
intensity (m/z 187.007), depicted with a dashed line on the
chromatogram in Figure S8. The coelutant was known to be p-
cresol sulfate, and is a major urinary metabolite of gut
microbial origin in metabolic proﬁling known to exist at high
concentrations. The coelutant was successfully removed in the
secondary fractionation. This demonstrates the successful
application of multiple rounds of puriﬁcation in a complex
mixture such as urine, enabling the physical puriﬁcation of
coeluting features of interest, which can be diﬃcult to purify in
a single step.
Feature B also presented chromatographic elution alongside
nearby peaks of an identical m/z. This can be observed from
the ES− chromatogram presented in the Figure S8.
First, it had to be determined if feature B was an individual
metabolite feature or if it was a split peak on the
chromatographic proﬁle. This was achieved using QTOF-
MS/MS collision energy dependent analysis (Figure S9a and
S9b). By repeating QTOF-MS/MS fragmentation with 5 V
step intervals of ﬁxed collision energy relative intensity of each
fragment was plotted (Figure S9c). Diﬀerences in the relative
fragment intensity at varying collision energies suggested each
chromatographic peak was represented by compounds with a
diﬀerent structural arrangement and therefore diﬀering bond
energies and hence fragment ion ratios. Therefore, feature B
was an ideal candidate to examine if the pipeline could be used
to purify and annotate features that had closely eluting isomers
that would share similarities in chemical structure and
therefore behave similarly chromatographically.
Initially, QTOF-MS was used to generate a high resolution
accurate mass and therefore predict the elemental composition
of the feature (C16H17NO8). QTOF-MS/MS had ES−
fragment ions indicative of the presence of a glucuronide
moiety (fragment ions 175.024 m/z and 113.024 m/z).
Through database searching (Pubchem,28 HMDB,2 Metlin,1
and ChEBI31) yielded a favored candidate, indole-3-acetic-
acid-O-glucuronide.
Following a successful two-step isocratic fractionation, a
puriﬁed sample of Fraction B was achieved and was then
decoupled from the pipeline and progressed to structural
annotation via 1H NMR spectroscopy and MRMS (Figure
S10).
Feature B Challenge 2: Stability during NMR Analysis.
Initially, the NMR analysis of the extracted features was
completed by resuspending the puriﬁed Feature B into a
phosphate buﬀer solution used for the NMR proﬁling of urine
samples.26 However, it was observed that the metabolite was
unstable in the buﬀer solution during the 2D NMR acquisition
experiments.
The 1H NMR spectra conﬁrmed that the feature of interest
was transforming over time to the isomeric species i and ii
(Figure S11). This irreversible transformation was also
conﬁrmed by UHPLC-MS analysis of the NMR solution of
the metabolite of interest (Figure S11).
The ability of acyl glucuronides to undergo spontaneous
hydrolysis and intramolecular rearrangements is well docu-
mented.32,33 It has been previously reported that the glycosidic
ester bond can migrate from position 1 to positions 2, 3, and 4
of glucuronic acid, and the rearrangement takes place in
phosphate buﬀer solution at pH 8.0.33 The ﬁrst step of the
transformation from position 1 to position 2 is irreversible
followed by further reversible steps.33 In addition, the double
UHPLC peaks for the isomers is thought to result from the
simultaneous presence of both α and β anomers of glucuronic
acid, which can also explain more complex shape of the 1H
NMR peaks of the isomers compared to the NMR signals of
the pure metabolite of interest (Figure S11).
To avoid the instability of the metabolite of interest in
solution, the feature was repuriﬁed and the NMR spectro-
scopic analyses were run in D2O containing only TSP as a
reference signal. In this way, the feature was stable in solution
for the whole duration of the 2D NMR characterization
including 1H−1H COSY and 1H−1H TOCSY experiments to
detect intercorrelations between the protons, and 1H−13C
HSQC and 1H−13C HMBC experiments to detect the
intercorrelations between protons and carbons in the molecule.
The metabolite of interest, Feature B, was annotated as indole-
3-acetic-acid-O-alpha-glucuronide. The full assignment is
shown in the Table S3, and 2D NMR spectra for the
metabolite of interest are presented in Figures S12 and S13.
Structure Elucidation of Urinary BiomarkersFeature C.
To annotate feature B, a two-step physical puriﬁcation was
required, however the pipeline was also tested to see if a
computation puriﬁcation step through statistical heterospec-
troscopy (SHY)27 could be implemented in the annotation of
some molecular species. Feature C was an unknown metabolite
at the time of puriﬁcation with an m/z of 283.082 that was also
present in fraction bank 87 along with feature B.
Initially, the elemental composition of feature C was
predicted using high resolution QTOF-MS data on the
primary negative ion (283.082 m/z) which was identiﬁed as
C13H16O7. MS/MS analysis (ES−) of feature C was consistent
with the presence of glucuronide moietythe loss of 176 Da
and the detection of characteristic fragments of glucuronic acid
(Figure S14a). The feature also shared similar fragment ions
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with p-cresol sulfate (107.05 m/z) that suggested p-cresol
within the structure. Database searching (Pubchem,28
HMDB,2 Metlin,1 and ChEBI31) suggested p-cresol glucur-
onide as a potential candidate.
A lack of purity meant it was not possible to immediately
annotate the unknown from NMR spectra. To overcome this,
several subfractions were collected with a distribution of the
feature over ﬁve subfractions. These were analyzed by
UHPLC-QTOF-MS and 1H NMR spectroscopy. The integrals
of the UHPLC-QTOF-MS signals of the unknown in all
subfractions were obtained from the proﬁles acquired in
negative ionization mode (m/z 283.082) and were correlated
to the full scan 1H NMR spectra using SHY (see Methods).
This enabled the identiﬁcation of the NMR spectral peaks that
were speciﬁcally associated with Feature C (Figure S14b).
The resultant 1H NMR spectrum was annotated and found
to have similarities with the NMR pattern of p-cresol sulfate:
two doublets in aromatic region at 7.06 (d) and 7.23 (d) ppm
(Figure 2signals 3,5 and signals 2,6, respectively) indicating
p-substitution in aromatic ring (Figure S14c.i); the intense
singlet at 2.30 (s) ppm for the methyl group of cresol (Figures
S14c.ii and 2, signal 7), and the signals in the sugar region 3.4−
4 ppm and a doublet at 5.07 ppm correspond to glucuronic
moiety (Figures S14c.iii and 2, signals 1′−5′). Signals in the
1H NMR were integrated to conﬁrm the number of hydrogens
in each of the chemical groups. These MS/MS and NMR data
together conﬁrm the annotation of feature C as p-cresol
glucuronide (Figure 2) that has been previously annotated in
animal urine.34,35
This example together with p-cresol sulfate show that the
pipeline is capable to readily extract urinary metabolites of gut-
microbial origin for which the authentic standards can be rarely
available. The combination of high-resolution MS and NMR
spectroscopic analyses together with statistical spectroscopic
methods provide a fast way for annotating these metabolites.
Structure Elucidation of Urinary BiomarkersFeature D.
Feature D was selected to test the pipeline as it was a late
eluting feature in RP chromatography. The feature was readily
puriﬁed under the RP chromatographic conditions that were
rapidly generated from the in-house isocratic database
described in the methods (Table S1) because of its high
retention time in the initial RP UHPLC-MS proﬁling (9.23
min), and therefore, higher hydrophobicity compared to the
other three features reported in this study. Both HRMS
QTOF-MS (Figure S15) and MRMS (Figure S16) analyses
generated the molecular formula as C27H44O8.
Following database searching (Pubchem,28 HMDB,2 Met-
lin,1 and ChEBI31), a potential candidate was suggested as
pregnanediol-3-glucuronide. The presence of glucuronide
moiety was conﬁrmed by QTOF MS/MS analysis (Figure
S15) through the loss of 176 Da and detection of characteristic
fragment of glucuronic acid in negative polarity. In this
instance, the standard of pregnanediol-3-glucuronide was
available for purchase, and it underwent analysis by UHPLC-
MS/MS and 1D 1H NMR spectroscopy along with the puriﬁed
metabolite, which conﬁrmed the identity of feature D (Figure
2). The NMR spectroscopic characterization of pregnanediol-
3-glucuronide and the full assignment was performed. The
spectra and the data are shown in SI (Figures S17 and S18 and
Table S4). Although pregnanediol-3-glucuronide has previ-
ously been reported as a biomarker in NMR metabolomics,36
this is the ﬁrst time that the full NMR assignment of
pregnanediol-3-glucuronide has been detailed in the literature.
■ CONCLUSIONS
Here, we present a systematic pipeline designed to structurally
elucidate and increase the annotation conﬁdence of unknowns
in urine metabolic proﬁling. These biomarkers are features of
interest in clinical/epidemiological studies and their structural
elucidation is key for the biological interpretation of the results.
By implementation of a novel ion exchange approach to desalt
urine, high precision multiple repeat fractionation can be
implemented using analytical scale chromatography instru-
mentation typical of a metabolite proﬁling laboratory, without
purchasing specialist preparative scale equipment. Minimal
column degradation was observed after multiple repeat
injections of one milliliter of concentrated urine, providing a
signiﬁcant beneﬁt to nondesalted urine.
The systematic pipeline results in the initial formation of a
reusable fraction bank that can become a laboratory resource
and revisited without time-consuming bulk urine preparation.
Downstream puriﬁcation can be done either through physical
secondary and tertiary chromatographic fractionation, or by
using computational puriﬁcation, via statistical heterospectro-
scopy in combination with NMR. To streamline the secondary
and tertiary chromatographic steps, an in-house reference
library of reversed-phase conditions was used to select a
development start point that enabled rapid optimization to
obtain maximum chromatographic resolution.
The proposed fraction bank workﬂow is advantageous as
puriﬁed metabolites can be decoupled from the pipeline at
each stage and can be sent to a combination of downstream
analytical technologies, including MRMS and NMR spectros-
copy for increased conﬁdence in structural elucidation. The
pipeline is particularly relevant where analytical standards
cannot be purchased, for example with biotransformed
metabolites, such as glucuronides, and an increase in
conﬁdence is required.
A limitation of the pipeline is the length of time required for
complete puriﬁcation and structural elucidation of unknowns.
Therefore, to help reduce this time window, a library of
isocratic conditions was created to help enable the rapid
selection of secondary and tertiary separation conditions.
However, despite this, overall pipeline time scales remain
constrained by the complexity of the NMR spectroscopic data
and the time taken for interpretation. For instance, in the
present work the structural elucidation of the feature C (p-
cresol glucuronide) took just several days while the full
structure assignment by NMR of the Feature D (pregnanediol-
3-glucuronide), which was not previously reported in the
literature and online databases, required several weeks due to
the highly complex NMR spectra. Therefore, the pipeline is
most suitable for scenarios where structural elucidation is
critical for the understanding and interpretation of the biology
behind key statistically signiﬁcant metabolites that would
otherwise remain unannotated and unknown.
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Vaźquez-Fresno, R.; Sajed, T.; Johnson, D.; Li, C.; Karu, N.; Sayeeda,
Z.; Lo, E.; Assempour, N.; Berjanskii, M.; Singhal, S.; Arndt, D.;
Liang, Y.; Badran, H.; Grant, J.; Serra-Cayuela, A.; Liu, Y.; Mandal, R.;
Neveu, V.; Pon, A.; Knox, C.; Wilson, M.; Manach, C.; Scalbert, A.
Nucleic Acids Res. 2018, 46 (D1), D608−D617.
(3) Horai, H.; Arita, M.; Kanaya, S.; Nihei, Y.; Ikeda, T.; Suwa, K.;
Ojima, Y.; Tanaka, K.; Tanaka, S.; Aoshima, K.; Oda, Y.; Kakazu, Y.;
Kusano, M.; Tohge, T.; Matsuda, F.; Sawada, Y.; Hirai, M. Y.;
Nakanishi, H.; Ikeda, K.; Akimoto, N.; Maoka, T.; Takahashi, H.; Ara,
T.; Sakurai, N.; Suzuki, H.; Shibata, D.; Neumann, S.; Iida, T.;
Tanaka, K.; Funatsu, K.; Matsuura, F.; Soga, T.; Taguchi, R.; Saito, K.;
Nishioka, T. J. Mass Spectrom. 2010, 45 (7), 703−714.
(4) Domingo-Almenara, X.; Montenegro-Burke, J. R.; Benton, H. P.;
Siuzdak, G. Anal. Chem. 2018, 90 (1), 480−489.
(5) Ruttkies, C.; Schymanski, E. L.; Wolf, S.; Hollender, J.;
Neumann, S. J. Cheminf. 2016, 8 (1), 3.
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